Phase 3
Completed N=150
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
Source: ClinicalTrials.gov NCT02159469 ↗Enrolled (actual)
150
Serious AEs
2.0%
Results posted
Jan 2018
Primary outcomePrimary: Percentage of Patients With Total Testosterone Cavg(0-168h) Serum Concentrations Within the Normal Range (300-1100 ng/dL) — 139 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With Total Testosterone Cavg(0-168h) Serum Concentrations Within the Normal Range (300-1100 ng/dL) |
139 | — |
| SECONDARY Safety and Tolerability |
125; 66; 3; 30; 1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Adult males aged ≥ 18 year of age with a documented diagnosis of hypogonadism
- Total testosterone levels 50 mL of blood or plasma within 3 months of screening.
- Donation of plasma or blood during study
Data sourced from ClinicalTrials.gov (NCT02159469). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.